Answers are grounded in this paper and cite their sources.
To fundamentally resolve the inherent limitations of conventional marine fish (salmon and trout)-derived polydeoxyribonucleotide (PDRN)—specifically residual animal protein allergenicity, intense fishy odor leading to behavioral aversion upon oral licking or topical application in companion animals (aversion rate: 47.5%), and marine heavy metal bioaccumulation risks—this study investigated the pharmaceutical optimization, cellular molecular mechanisms, and preclinical efficacy and safety of a topical mist formulation specifically designed for companion animals (canine and feline). The formulation combines highly purified Phyto-PDRN derived from Aloe vera adventitious roots and Centella asiatica (Cica-PDRN; Sodium DNA, 50–1,500 bp) with dexpanthenol (1.0–1.5%), a pivotal epidermal barrier-repair agent, classified as an animal quasi-drug external topical liquid. Unlike human skin, companion animals possess a fragile stratum corneum composed of merely 3–5 cell layers and maintain a neutral to weakly alkaline epidermal surface pH (canine pH 6.2–7.5; feline pH 6.0–7.2). Accordingly, the final formulation was precisely buffered to pH 6.8–7.2. In an oil-free, water-based aerosol system, the severe nozzle-clogging issue associated with poorly soluble ceramide NP (0.05%) was completely resolved via a liquid nano-solubilization premix technology. Regarding antimicrobial preservation, six harmful synthetic preservatives (including parabens and phenoxyethanol) were entirely excluded; instead, an EWG Grade 1 natural multi-preservative booster system consisting of 1,2-hexanediol (1.0%), sodium phytate (0.05%), and ethylhexylglycerin (0.05%) was established, satisfying USP <51> antimicrobial effectiveness criteria and validating a 24-month shelf-life stability (via 6-month accelerated testing at 40°C/75% RH). In vitro bioactivity evaluations demonstrated that the Aloe and Centella PDRN complex exhibited an outstanding DPPH free radical scavenging activity of 96.0%. In human epidermal keratinocytes (HaCaT) and dermal fibroblasts (HDF), the complex markedly upregulated the gene expressions of antioxidant enzyme SOD1 (135.2%), epidermal barrier structural proteins filaggrin (FLG, 128.4%) and loricrin (LOR, 132.8%), and type I collagen (COL1A1, 142.1%), while potently suppressing matrix metalloproteinase-1 (MMP-1) expression to 48.3%. In particular, selective purinergic adenosine A2A receptor (A2AR) activation accelerated fibroblast proliferation by 215.4% (which was abrogated to 112.1% by the selective A2AR antagonist ZM241385, verifying the specific molecular mechanism) and promoted 94.8% scratch wound closure within 24 h. In cellular and animal preclinical models, the formulation protected feline renal epithelial cells (CRFK) against severe oxidative cytopathy, restoring cell viability to 94.1% and decreasing TUNEL-positive apoptotic cells to 8.2%. In BALB/c mice with full-thickness cutaneous excision wounds, the mist complex induced 96.8% re-epithelialization on day 14 alongside robust neo-capillary CD31 angiogenesis and dense collagen remodeling. Moreover, the formulation demonstrated zero mucosal ocular irritation in the chorioallantoic membrane (HET-CAM score 0.0) and achieved exceptional palatability and acceptance rates (90.0–93.3%) in dogs and cats. Consequently, this study successfully establishes the scientific foundation for an oral-safe, 100% vegan animal quasi-drug mist formulation and validates its commercialization and contract development and manufacturing organization (CDMO) viability.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: